» Articles » PMID: 8157571

Characterization of a Beta-lactamase from Clostridium Clostridioforme

Overview
Date 1994 Jan 1
PMID 8157571
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

A beta-lactamase-producing strain of Clostridium clostridioforme isolated from human peritoneal fluid was examined by MIC testing and enzyme characterization. MICs of penicillins (64-512 mg/L) were higher than those of cephalosporins (8-128 mg/L); the strain was susceptible to cefoxitin (8 mg/L) and imipenem (1 mg/L). No enhancement of cephalosporin activity occurred when clavulanate was also added, but a limited degree of enhancement of penicillin activity (resulting in beta-lactam MICs higher than available NCCLS breakpoints) occurred when clavulanate, sulbactam or tazobactam was added simultaneously. By contrast, addition of BRL 42715 with amoxycillin, ticarcillin or piperacillin led to a drop in beta-lactam MICs from 512 to < or = 1 mg/L, with a drop from 64 to 1 mg/L when BRL 42715 was added with cefotaxime. All inhibitors were added at fixed concentrations of 2 mg/L. As determined spectrophotometrically, the enzyme hydrolysed penicillin G, cloxacillin and piperacillin (Vmax values (%) 372, 1816, 1001, respectively relative to cephaloridine) more efficiently than cephalosporins (69-191, with cephaloridine as 100%). Km values (microM) varied between 30-308 microM (penicillins) and 2-20 microM (cephalosporins). Relative enzyme efficiency (relative Vmax/Km with cephaloridine as 100) varied from 21-100 (cephalosporins) and 8-77 (penicillins). IC50 values (microM) with nitrocefin, piperacillin and penicillin G substrates (concentrations 20, 100 and 20 microM, respectively) were > 1000, 7, 3.5 (clavulanate); > 1000, 300, 59 (sulbactam), > 1000, 29, 7.7 (tazobactam); 0.0004, 0.001, 0.0018 (BRL 42715). The enzyme was not inhibited by EDTA, cefoxitin, cloxacillin or aztreonam, but was inhibited by pCMB.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Clostridium neonatale antimicrobial susceptibility, genetic resistance determinants, and genotyping: a multicentre spatiotemporal retrospective analysis.

Ferraris L, Delannoy J, Mazuet C, Diancourt L, Mesa-Schein V, Barbut F J Antimicrob Chemother. 2023; 79(2):271-279.

PMID: 38084883 PMC: 10832599. DOI: 10.1093/jac/dkad369.


Recent Trends in Antimicrobial Resistance among Anaerobic Clinical Isolates.

Reissier S, Penven M, Guerin F, Cattoir V Microorganisms. 2023; 11(6).

PMID: 37374976 PMC: 10302625. DOI: 10.3390/microorganisms11061474.


Characterization of vancomycin-resistance gene clusters in the human intestinal microbiota by metagenomics and culture-enriched metagenomics.

Brochu E, Huletsky A, Boudreau D, Raymond F, Berube E, Ouameur A JAC Antimicrob Resist. 2023; 5(2):dlad026.

PMID: 36968950 PMC: 10036994. DOI: 10.1093/jacamr/dlad026.


Regulation and Anaerobic Function of the β-Lactamase.

Sandhu B, Edwards A, Anderson S, Woods E, McBride S Antimicrob Agents Chemother. 2019; 64(1).

PMID: 31611350 PMC: 7187622. DOI: 10.1128/AAC.01496-19.


Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik's Cube of Clinical Microbiology?.

Gajdacs M, Spengler G, Urban E Antibiotics (Basel). 2017; 6(4).

PMID: 29112122 PMC: 5745468. DOI: 10.3390/antibiotics6040025.